首页 | 官方网站   微博 | 高级检索  
     

葛根素注射液辅助治疗急性前壁心肌梗死的系统评价
引用本文:吴嘉瑞,张晓朦,张冰. 葛根素注射液辅助治疗急性前壁心肌梗死的系统评价[J]. 中国实验方剂学杂志, 2014, 20(11): 213-217
作者姓名:吴嘉瑞  张晓朦  张冰
作者单位:北京中医药大学, 北京 100102;北京中医药大学, 北京 100102;北京中医药大学, 北京 100102
基金项目:国家科技支撑计划项目(2006BAI21B11)
摘    要:目的:系统评价葛根素注射液辅助治疗急性前壁心肌梗死的疗效及安全性。方法:全面收集葛根素注射液用于辅助治疗急性前壁心肌梗死的随机对照试验,采用Cochrane风险评价表评价其研究质量,提取资料并通过RevMan 5.2进行Meta分析。结果:共纳入6篇文献,共计受试者354例,1篇文献采用抽签确定随机序列,其他均未提及随机分组方法及盲法。Meta分析显示,葛根素注射液辅助西医常规疗法治疗急性前壁心肌梗死具有较好的疗效,可以有效降低QRS记分[MD=-1.69,95%CI(-2.07,-1.32),P<0.000 01],提高左心室射血分数[MD=12.18,95%CI(2.97,21.39),P=0.010],减少梗死面积[MD=-9.46,95%CI(-11.37,-7.55),P<0.000 01],提高红细胞超氧化物歧化酶(SOD)值[MD=611.47,95%CI(464.80,758.14),P<0.000 01],降低死亡率,仅报道1例不良事件。结论:葛根素注射液辅助治疗前壁心肌梗死具有较好的疗效和安全性。

关 键 词:葛根素注射液  急性前壁心肌梗死  系统评价  随机对照试验
收稿时间:2013-06-28

Systemic Review of Puerarin Injection of Adjuvant Therapy for Acute Anterior Wall Myocardial Infarction
WU Jia-rui,ZHANG Xiao-meng and ZHANG Bing. Systemic Review of Puerarin Injection of Adjuvant Therapy for Acute Anterior Wall Myocardial Infarction[J]. China Journal of Experimental Traditional Medical Formulae, 2014, 20(11): 213-217
Authors:WU Jia-rui  ZHANG Xiao-meng  ZHANG Bing
Affiliation:Beijing University of Chinese Medicine, Beijing 100102, China;Beijing University of Chinese Medicine, Beijing 100102, China;Beijing University of Chinese Medicine, Beijing 100102, China
Abstract:Objective:To evaluate systematically the clinical efficacy and safety of puerarin injection for the adjuvant therapy of acute anterior wall myocardial infarction. Method:Randomized controlled trials (RCTs) about puerarin injection for acute anterior wall myocardial infarction were searched systemically and comprehensively. Two reviewers assessed the quality of the included studies by the Cochrane risk of bias, and extracted the information from them. Meta-analysis was conducted with the software Review Manager 5.2. Result:A total of 6 studies with 354 participants were included, and the quality of the studies was relatively low. There was only one study to generate random sequence by drawing lots. In the meta-analysis, the results of puerarin group were significantly superior to the west conventional therapy group in decreasing the score of QRS[MD=-1.69, 95%CI (-2.07,-1.32), P<0.000 01], reducing the infarct size[MD=-9.46, 95%CI(-11.37,-7.55), P<0.000 01], increasing the ejection fraction left ventricular ejection fraction(LVEF)[MD=12.18, 95%CI (2.97, 21.39), P=0.010] and erythrocyte superoxide dismutase(SOD) values[MD=611.47, 95%CI (464.80,758.14), P<0.000 01],and reducing mortality rate, and so on. And there was only 1 adverse drug reaction (ADR) reported, more quality studies should be included. Conclusion:Comparing with the conventional therapy of the control group used for treating acute anterior wall myocardial infarction, puerarin injection combined with the conventional therapy was relatively effective and safety, which was based on the systematic review.
Keywords:puerarin injection  acute anterior wall myocardial infarction  systemic review  randomized controlled trials
本文献已被 CNKI 等数据库收录!
点击此处可从《中国实验方剂学杂志》浏览原始摘要信息
点击此处可从《中国实验方剂学杂志》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号